Inactive Instrument

Taiwan Liposome Company, Ltd.

4152

TW0004152004

Biotechnology & Medical Research

Taiwan Liposome Company, Ltd. Announces Appointment of George Spencer-Green as Chief Medical Officer

January 25, 2019 at 01:27 am EST

Taiwan Liposome Company, Ltd. announced the appointment of George Spencer-Green as Chief Medical Officer. George Spencer-Green is the former clinical head of Pfizer's biosimilars development program.

Latest news about Taiwan Liposome Company, Ltd.

Endo Ventures Limited Executes Agreement with Taiwan Liposome Company, Ltd. to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain	22-06-13	CI
TLC BioSciences Announces Publication of Tlc599 Phase Ii Results in Arthritis Research & Therapy	22-03-07	CI
Woods Investment Company, Ltd. completed the acquisition of Taiwan Liposome Company, Ltd. from a group of sellers.	21-10-07	CI
Taiwan Liposome Company, Ltd.(NasdaqGM:TLC) dropped from NASDAQ Composite Index	21-09-29	CI
Taiwan Liposome : to Voluntary Delist From Nasdaq	21-09-08	MT
TAIWAN LIPOSOME : HC Wainwright Lowers Taiwan Liposome to Neutral From Buy, Price Target to $7.50 From $11	21-07-13	MT
TAIWAN LIPOSOME : Laidlaw Downgrades Taiwan Liposome to Hold From Buy	21-07-07	MT
Woods Investment Company, Ltd. agreed to acquire Taiwan Liposome Company, Ltd. from a group of sellers for TWD 9.2 billion.	21-07-04	CI
Taiwan Liposome Company, Ltd. and Endo International plc Enter a Commercialization Agreement for A Liposomal Product	21-07-01	CI
TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India	21-05-27	CI
Taiwan Liposome : Working With Zydus Healthcare to Provide Supply of AmphoTLC in India	21-05-26	MT
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India	21-05-26	CI
Taiwan Liposome : TLC Secures India's Approval For Mucormycosis Treatment AmphoTLC	21-05-25	MT
Taiwan Liposome : Earnings Flash (TLC) TLC Posts Q1 Loss $-0.08	21-05-14	MT
Taiwan Liposome Company, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Taiwan Liposome Company, Ltd. announced a financing transaction	21-03-29	CI
Taiwan Liposome Company, Ltd. Provides Clinical Trail Update	21-02-05	CI
Taiwan Liposome Company, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-04	CI
Sector Update: Health Care Stocks Flat During Premarket Trading on Monday	20-12-28	MT
Taiwan Liposome : Completes Patient Enrollment in Study of TLC599 in Patients With Osteoarthritis Knee Pain	20-12-28	MT
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain	20-12-28	CI
Taiwan Liposome Company, Ltd. Announces Management Changes	20-12-22	CI
Taiwan Liposome : Reports 98% Enrollment of Phase 3 Study of Osteoarthritis Drug	20-12-18	MT
TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program	20-11-03	CI
Taiwan Liposome Company, Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-27	CI

Chart Taiwan Liposome Company, Ltd.

Duration

Period

More charts

Taiwan Liposome Company, Ltd. is a Taiwan-based company principally engaged in the research and development and commercialization of lipid drug delivery systems. The Company is engaged in the development of special generic drugs, new formulas and new drugs using patents. The Company's therapeutic areas include pain management, eye diseases and cancer. Its anticancer medicine product named Lipo-Dox has been distributed in domestic and Asian markets.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.77%	125B
REGENERON PHARMACEUTICALS, INC.	+14.05%	108B
BIONTECH SE	-7.16%	23.64B
ARGENX SE	+2.71%	22.39B
GENMAB A/S	-11.81%	17.78B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.47%	16.34B
NEUROCRINE BIOSCIENCES, INC.	+2.23%	13.56B
SAREPTA THERAPEUTICS, INC.	+27.13%	11.59B

Bio Therapeutic Drugs